Pipeline Therapeutics
Christopher Baccei has held a variety of roles in the scientific field since 1997. Christopher began their career as a Research Assistant II at Yale University, followed by a Staff Research Biologist at Merck in 2000. In 2005, they took on the role of Associate Scientist at Kalypsys Inc. and then Senior Research Associate II at Amira Pharmaceuticals in 2006. In 2011, they became a Research Scientist II at Inception Sciences, and most recently, a Principal Scientist at Pipeline Therapeutics in 2018.
Christopher Baccei attended Duke University from 1993 to 1996, where they earned a Bachelor of Science in Biology, General.
Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination, and axonal repair.